RESEARCH IN PULMONARY HYPERTENSION

"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center


Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now twelve PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.

PHA’s Research Program

PHA’s Research Program has committed more than $15 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported 70 promising researchers through four independently reviewed, cutting-edge research programs. Read more about PHA’s Research Program

Learn more

Current Treatments

PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments

Research Corner in Pathlight

Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more

Pulmonary Hypertension Research News
Elusive Origin of Pulmonary Hypertension Uncovered

From Brigham and Women’s Hospital - A new study published in EMBO Molecular Medicine by researchers from Brigham and Women’s Hospital (BWH) sheds light on the disease’s surprising cause, with crucial implications for diagnosis, treatment, and prevention of PH in persons at risk. Read more.


Monday, April 06, 2015 2:15:00 PM

Selexipag (Uptravi) Long-term Outcome Data in PAH Presented

From PipelineReview.com - Yesterday, key long-term outcome data from Actelion's pivotal selexipag (Uptravi®) Phase III GRIPHON study were shared during an oral presentation at the American College of Cardiology (ACC) Congress in San Diego, Calif. The presentation highlighted that the investigational drug selexipag significantly reduced the risk of a morbidity/mortality event by 40 percent versus placebo (p<0.0001) in patients with pulmonary arterial hypertension (PAH). Read article


Tuesday, March 17, 2015 11:33:00 AM

Quebec Breathes New Hope into Lives of Those Affected by Pulmonary Arterial Hypertension

(CNW) - The Pulmonary Hypertension Association of Canada (PHA Canada) was pleased to learn that a new treatment option for pulmonary arterial hypertension (PAH) is now being publicly funded in the province of Quebec. On October 1, the Institut national d'excellence en santé et services sociaux (INESSS) recommended that the drug Opsumit (macitentan) be added to the list of drugs covered by the prescription drug insurance plan administered by the Régie de l'assurance maladie du Québec (RAMQ). Read the full press release


Tuesday, October 21, 2014 8:49:00 AM

PHA Accredits First Six PH Care Centers; Application Process Now Open

We are excited to announce that we have accredited our first six Pulmonary Hypertension Care Centers (PHCC). This initiative aims at improving overall quality of care and ultimately improving outcomes of patients with pulmonary hypertension.

Two types of centers will be accredited: Centers of Comprehensive Care (CCC) - the first six are listed below - and Regional Clinical Programs (RCP). For interested centers, the PHCC Application is now open and available for download. Many PH programs have already submitted their application, and you can track their progress on the Applicant Center page.

Quality Care from Experts in the Field

“The PHCC will give PH patients security in knowing they are receiving quality care from the experts in the field,” said Dr. Murali Chakinala, from the Washington University School of Medicine and PHCC Committee Chair. “Patients can feel confident that the PHCCs have been vetted by a rigorous process that includes a detailed application and a comprehensive site visit with ultimate adjudication by a Committee of more than 20 health professionals with vast experience in caring for PH patients.”

PHA's Scientific Leadership Council and the PHCC Oversight Committee set high parameters for PHCC accreditation. PHCC accreditation signifies that a PH program has demonstrated a dedication to making proper diagnosis and capacity to appropriately and comprehensively manage PH patients through a set of criteria established by the PHA Scientific Leadership Council – 28 global leaders in the field of pulmonary hypertension. These criteria have also been developed with input from many PH stakeholders including physicians, allied health care professionals, patients and PHA leadership and are considered essential to delivering high-quality care for these complex patients.

Patient Registry for Determining Effective Care


Accredited PH Care Centers will also contribute to a PH patient registry that will track diagnostic and treatment patterns at a national level, ultimately demonstrating quality improvement for the care of PH patients.

“The PH patient registry will provide important data on the care and outcomes of patients with pulmonary hypertension across the country,” said Dr. Steven Kawut of the Perelman School of Medicine at the University of Pennsylvania. “We can then begin to understand best practices in the treatment of PH and continue to improve the quality of life and survival of individuals with this disease.”

Linking Centers through a national network will increase collaboration in the PH community, through clinical, quality improvement and investigative partnership.

First Six Accredited Centers

  1. Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Fairfax, Va.
  2. Penn Pulmonary Hypertension / Pulmonary Vascular Disease Program, University of Pennsylvania Health System and Perelman School of Medicine, Philadelphia, Pa.
  3. Kentuckiana Pulmonary Associates, Louisville, Ky.
  4. UC Health Pulmonary Hypertension Program, University of Cincinnati, Cincinnati, Ohio.
  5. Cottage Pulmonary Hypertension Center, Cottage Health System, Santa Barbara, Calif.
  6.  Stanford Pulmonary Hypertension Program, Stanford University, Stanford, Calif.

For more information on PHCC visit www.PHAssociation.org/PHCareCenters or email PHCC@PHAssociation.org.

 


Wednesday, October 01, 2014 1:44:00 PM

Screen Scleroderma Patients Annually for Pulmonary Hypertension

Scleroderma patients should be screened every year for pulmonary hypertension even if they are recently diagnosed and have no respiratory symptoms. Noninvasive tests can catch pulmonary problems early, and treatments are available to slow the progression of scleroderma. Read more and watch the video


Friday, September 19, 2014 1:42:00 PM

FacebookTwitterLinkedInYouTube

For optimal viewing of PHAssociation.org, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.